When to Choose Tenex vs Intuniv
Intuniv (guanfacine extended-release) should be the default choice for ADHD treatment in patients aged 6 years and older, while Tenex (immediate-release guanfacine) has no established role in ADHD management and should not be substituted on a milligram-per-milligram basis. 1
FDA-Approved Indication and Formulation Differences
Intuniv is FDA-approved for ADHD as both monotherapy and adjunctive therapy to stimulants in children and adolescents ages 6-17 years. 1
Tenex (immediate-release guanfacine) is NOT FDA-approved for ADHD—it is approved only for hypertension. 2, 3
The two formulations are pharmacokinetically distinct and cannot be interchanged: Intuniv has a delayed Tmax, reduced Cmax, and lower bioavailability compared to the same dose of immediate-release guanfacine. 1
If switching from immediate-release to extended-release guanfacine, the FDA label explicitly states to discontinue Tenex and titrate Intuniv from 1 mg/day according to the standard dosing schedule—not to substitute on a mg-per-mg basis. 1
Clinical Scenarios Favoring Intuniv
Once-Daily Dosing and Adherence
Intuniv provides 24-hour symptom coverage with once-daily administration (morning or evening), improving adherence compared to multiple daily doses of immediate-release formulations. 1, 2
Extended-release formulation reduces peak-related adverse effects (sedation, hypotension) while maintaining therapeutic efficacy throughout the day. 2, 4
Evidence-Based ADHD Treatment
Multiple controlled trials demonstrate Intuniv efficacy for ADHD core symptoms (inattention and hyperactivity-impulsivity) in children and adolescents. 1, 5
Meta-analysis of 12 RCTs (2,653 participants) confirms significant treatment response: 58.5% with guanfacine extended-release vs 29.4% with placebo in trials <10 weeks, and 63.6% vs 39.7% in trials >10 weeks. 5
Guanfacine extended-release is superior to atomoxetine and as effective as clonidine extended-release for ADHD, with a more favorable side effect profile than immediate-release formulations. 4
Adjunctive Therapy with Stimulants
Intuniv is FDA-approved as adjunctive therapy to psychostimulants, providing round-the-clock symptom control without additional stimulant exposure. 6, 1
Combination treatment (methylphenidate + guanfacine extended-release) shows superior EEG correlates of treatment response and greater ADHD symptom improvement compared to monotherapy in some patients. 7, 8
Weight-Adjusted Dosing for Optimal Efficacy
Clinically relevant improvements begin at 0.05-0.08 mg/kg once daily, with doses up to 0.12 mg/kg potentially providing additional benefit if tolerated. 1, 9
Weight-adjusted dosing balances exposure-related benefits against dose-dependent risks (hypotension, bradycardia, sedation). 1
When Immediate-Release Has Been Studied (Not for ADHD)
Immediate-release guanfacine at 3 mg/day has been studied off-label for smoking cessation, heroin withdrawal, and migraine prophylaxis—not ADHD. 10
Pharmacokinetic equivalency research shows 3 mg/day immediate-release ≈ 4 mg/day extended-release in plasma levels at 24 hours, but this was studied in adult smokers, not ADHD patients. 10
Critical Safety Monitoring (Applies to Both Formulations)
Measure heart rate and blood pressure before initiation, after dose increases, and periodically during treatment to detect hypotension and bradycardia. 1
Most common adverse events with Intuniv: somnolence (38.6%), headache (20.5%), fatigue (15.2%), with approximately 80% experiencing at least one treatment-emergent adverse event. 5, 11
Discontinuation requires tapering in decrements of no more than 1 mg every 3-7 days to minimize rebound hypertension. 1
Age-Specific Considerations
For children under 6 years old, extended-release guanfacine lacks sufficient evidence and is not recommended per AAP guidelines. 12
For adults with ADHD, guanfacine extended-release demonstrates efficacy and safety in Japanese and other populations, though more clinical studies are needed. 5, 11
Common Pitfalls to Avoid
Never substitute immediate-release for extended-release on a mg-per-mg basis—the pharmacokinetic profiles differ substantially. 1
Do not administer Intuniv with high-fat meals due to increased drug exposure. 1
Do not crush, chew, or break Intuniv tablets—this increases the rate of guanfacine release and eliminates the extended-release properties. 1
Avoid using immediate-release guanfacine for ADHD—it lacks FDA approval and controlled trial evidence for this indication. 2, 3